Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Autologous Renal Cell Carcinoma Tumor Lysate-Pulsed Dendritic Cell Vaccine

A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with renal cell carcinoma (RCC) tumor cell lysate containing tumor associated antigens (TAAs) with potential immunostimulatory and antineoplastic activities. Upon administration, autologous renal cell carcinoma tumor lysate-dendritic cell vaccine may stimulate anti-tumoral cytotoxic T-lymphocyte (CTL) and antibody responses against RCC tumor cells expressing RCC TAAs, resulting in RCC tumor cell lysis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Abbreviation:autologous RCC tumor lysate-DC vaccine
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search